# A Trial to Compare Blood Concentration Levels of Semaglutide Following Subcutaneous Injections of Semaglutide 1 mg by 2 Different Devices (the DV3372 Device and by the PDS290 Semaglutide Pen-injector)

> **NCT03611322** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 54 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Semaglutide, 0.25 mg
- **DRUG:** Semaglutide, 0.5 mg
- **DRUG:** Semaglutide, 1.0 mg
- **DEVICE:** DV3372
- **DEVICE:** PDS290 pen-injector

## Key facts

- **NCT ID:** NCT03611322
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-08
- **Primary completion:** 2019-01-07
- **Final completion:** 2019-01-07
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2020-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03611322

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03611322, "A Trial to Compare Blood Concentration Levels of Semaglutide Following Subcutaneous Injections of Semaglutide 1 mg by 2 Different Devices (the DV3372 Device and by the PDS290 Semaglutide Pen-injector)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03611322. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*